Teva Pharmaceutical Industries (NYSE:TEVA) had its target price decreased by equities researchers at Leerink Swann from $17.00 to $16.00 in a research report issued on Friday. The brokerage presently has an “underperform” rating on the stock. Leerink Swann’s price objective indicates a potential downside of 14.02% from the stock’s previous close.

A number of other research analysts have also recently weighed in on the company. Goldman Sachs Group raised their price target on Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, January 11th. Credit Suisse Group restated an “underperform” rating and issued a $8.00 price target (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, November 6th. Morgan Stanley upgraded Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 price target for the company in a research report on Friday, December 15th. Royal Bank of Canada set a $11.00 price target on Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Wednesday, November 29th. Finally, Cantor Fitzgerald set a $10.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, December 14th. Ten research analysts have rated the stock with a sell rating, seventeen have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $21.15.

Shares of Teva Pharmaceutical Industries (TEVA) opened at $18.61 on Friday. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $37.94. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The company has a market capitalization of $19,330.00, a price-to-earnings ratio of -1.15, a price-to-earnings-growth ratio of 1.35 and a beta of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the business posted $1.38 earnings per share. The business’s revenue for the quarter was down 15.9% on a year-over-year basis. equities research analysts expect that Teva Pharmaceutical Industries will post 2.75 EPS for the current year.

A number of institutional investors have recently bought and sold shares of TEVA. Cornerstone Capital Management Holdings LLC. grew its holdings in Teva Pharmaceutical Industries by 308.1% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 75,900 shares of the company’s stock valued at $2,521,000 after buying an additional 57,300 shares during the period. State Street Corp grew its holdings in Teva Pharmaceutical Industries by 5.1% in the 2nd quarter. State Street Corp now owns 4,763,692 shares of the company’s stock valued at $158,254,000 after buying an additional 232,924 shares during the period. Caxton Associates LP grew its holdings in Teva Pharmaceutical Industries by 6.6% in the 2nd quarter. Caxton Associates LP now owns 13,000 shares of the company’s stock valued at $432,000 after buying an additional 800 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in Teva Pharmaceutical Industries by 10.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 159,633 shares of the company’s stock valued at $5,303,000 after buying an additional 15,038 shares during the period. Finally, Bank of Nova Scotia grew its holdings in Teva Pharmaceutical Industries by 8.3% in the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock valued at $229,000 after buying an additional 528 shares during the period. Hedge funds and other institutional investors own 51.99% of the company’s stock.

WARNING: This report was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://theolympiareport.com/2018/02/11/teva-pharmaceutical-industries-teva-price-target-cut-to-16-00.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.